<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Accumulating evidence has suggested that Mothers against decapentaplegic homolog 7 (SMAD7) rs12953717 polymorphism might be related to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="1" pm="."><plain>However, epidemiologic findings have been inconsistent </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore performed a meta-analysis to clarify the association between the SMAD7 rs12953717 polymorphism and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A comprehensive search was conducted to identify <z:hpo ids='HP_0000001'>all</z:hpo> eligible studies of SMAD7 rs12953717 polymorphism and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="4" pm="."><plain>We used odds ratios (ORs) to assess the strength of the association, and 95% confidence intervals (CIs) to give a sense of the precision of the estimate </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0001425'>Heterogeneity</z:hpo>, publication bias, and sensitivity analysis were also explored </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: A total of 14 case-control studies, including 16928 cases and 14781 controls, were included in the present meta-analysis </plain></SENT>
<SENT sid="7" pm="."><plain>The overall results showed that the variant genotypes were associated with a significantly increased risk of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types (homozygote comparison, OR = 1.23, 95%CI = 1.10-1.38, P&lt;0.01; heterozygote comparison, OR = 1.12, 95%CI = 1.02-1.22, P = 0.02; recessive model, OR = 1.17, 95%CI = 1.07-1.29, P&lt;0.01; dominant model, OR = 1.15, 95%CI = 1.06-1.25, P&lt;0.01; allelic model, OR = 1.12, 95%CI = 1.06-1.18, P&lt;0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Further sensitivity analysis confirmed the significant association </plain></SENT>
<SENT sid="9" pm="."><plain>In the subgroup analysis by ethnicity, SMAD7 rs12953717 polymorphism was significantly associated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk in both Caucasians and Asians </plain></SENT>
<SENT sid="10" pm="."><plain>In the subgroup analysis by <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types, SMAD7 rs12953717 polymorphism was significantly associated with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Our investigations demonstrate that rs12953717 polymorphism is associated with the susceptibility of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Large-scale and well-designed case-control studies are necessary to validate the risk identified in the present meta-analysis </plain></SENT>
</text></document>